AttendMe Owl Logo
AttendMe
Evidence Evolution
Trauma SurgeryTrauma Surgery

How This Evidence Evolved

Permissive Hypotension in Trauma

From Aggressive Crystalloid to Targeted Hypotensive Resuscitation

31.5

Timeline

Stern 1993
1993
Bickell 1994
1994
Dutton 2002
2002
Morrison 2011
2011
European guideline on management of major bleeding and coagulopathy following trauma, sixth edition
2023
Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

A near-fatal hemorrhage experiment in 27 swine tested resuscitation to mean arterial pressures of 40, 60 or 80 mmHg after a vascular injury. Mortality was 78% in the 80-mmHg group versus 11% and 22% in the lower-target groups. Intraperitoneal hemorrhage volume was also greater at the highest target. The study showed that attempts to restore blood pressure with crystalloid could worsen bleeding and mortality in this animal model. It did not establish a safe human target. Later European guidance recommends restricted volume replacement in bleeding trauma patients without clinical evidence of brain injury.
Proof

Landmark RCTs and pivotal trials that established the evidence base

The Bickell trial in 1994 compared immediate and delayed fluid resuscitation in 598 adults with penetrating torso injuries and prehospital SBP ≤90 mmHg. The delayed group received IV cannulation but no fluid resuscitation until the operating room. Survival to hospital discharge was 70% with delayed versus 62% with immediate resuscitation (P=0.04). Among postoperative survivors, complications occurred in 55/238 (23%) versus 69/227 (30%) (P=0.08), and hospitalization was shorter with delayed resuscitation. The study used a single centralized prehospital system and a single receiving facility.
Extension

Follow-up studies, subgroup analyses, and real-world validation

Dutton and colleagues randomized 110 patients to target SBP >100 mmHg or 70 mmHg until definitive hemostasis. Observed SBP differed significantly: 114 versus 100 mmHg (P<0.001). There were four deaths in each group. Morrison and colleagues studied the first 90 patients in a trial of intraoperative MAP targets of 50 versus 65 mmHg, reporting lower blood product and IV fluid use and less immediate postoperative coagulopathy with the lower target. The 2023 European guideline recommends restricted volume replacement targeting SBP 80–90 mmHg until major bleeding stops when there is no clinical evidence of brain injury. Severe TBI requires a different target: MAP ≥80 mmHg.
Guidelines

Integration into clinical practice guidelines and recommendations

The European trauma bleeding guideline, sixth edition, recommends restricted volume replacement with SBP 80–90 mmHg (MAP 50–60 mmHg) until major bleeding stops in patients without clinical evidence of brain injury (Grade 1B). For severe TBI (GCS ≤8), it recommends MAP ≥80 mmHg (Grade 1C).
European guideline on management of major bleeding and coagulopathy following trauma, sixth edition

Without brain injury: SBP 80–90 mmHg until bleeding control (Grade 1B); severe TBI (GCS ≤8): MAP ≥80 mmHg (Grade 1C).

European guideline on management of major bleeding and coagulopathy following trauma, sixth edition

Use restricted volume replacement targeting SBP 80–90 mmHg (MAP 50–60 mmHg) until major bleeding stops without clinical evidence of brain injury (Grade 1B). Maintain MAP ≥80 mmHg in severe TBI (GCS ≤8; Grade 1C).

Now

Current standard of care and ongoing research directions

European guidance recommends SBP 80–90 mmHg until bleeding control without brain injury, but MAP ≥80 mmHg in severe TBI. Permissive hypotension requires caution in older patients and may be contraindicated with chronic arterial hypertension; it is contraindicated with TBI or spinal injury. Blood lactate is recommended to estimate and monitor bleeding and tissue hypoperfusion, with base deficit as an alternative if lactate is unavailable. If red-cell transfusion is necessary, the recommended target hemoglobin is 70–90 g/L; during rapidly evolving hemorrhagic shock, transfusion decisions should not rely on hemoglobin alone. These are distinct monitoring and transfusion recommendations, rather than evidence that a lower blood pressure is appropriate for every injured patient.

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

What blood pressure target should be used in permissive hypotension?+
The 2023 European guideline recommends restricted volume replacement targeting SBP 80–90 mmHg (MAP 50–60 mmHg) until major bleeding stops in patients without clinical evidence of brain injury (Grade 1B). In severe TBI (GCS ≤8), maintain MAP ≥80 mmHg (Grade 1C).
Why is permissive hypotension contraindicated in traumatic brain injury?+
Permissive hypotension and restrictive volume resuscitation are contraindicated in patients with TBI or spinal injuries. Adequate perfusion pressure is crucial for oxygenation of the injured central nervous system, and rapid bleeding control is particularly important. The 2023 European guideline recommends MAP ≥80 mmHg for severe TBI (GCS ≤8; Grade 1C).
How much crystalloid is too much in trauma resuscitation?+
The 2023 European guideline recommends initiating 0.9% sodium chloride or a balanced crystalloid solution in hypotensive bleeding trauma patients (Grade 1B), within a restricted volume replacement strategy. If 0.9% sodium chloride is used, it should be limited to a maximum of 1–1.5 L.
Does permissive hypotension apply to elderly trauma patients?+
Permissive hypotension needs careful consideration in older trauma patients and may be contraindicated in patients with chronic arterial hypertension.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026